Introduction
============

*Salmonella enterica* serovar Typhimurium (*S.typhi murium*) is a bacterial pathogen that invades and replicates within a membrane-bound compartment (*Salmonella*-containing vacuole; SCV) inside a variety of host cell types. The biogenesis and maturation of the SCV has been studied in detail in both macrophages and epithelial cells. Within a few minutes of bacterial entry, components of the early endocytic pathway, such as EEA1 and the transferrin receptor, are recruited to the SCV (early SCV; [@cdg517c24]; [@cdg517c32]). These proteins are then gradually lost, and interactions between the SCV and late endosomal compartments lead to the progressive acquisition of the vacuolar ATPase and several lysosomal membrane proteins (lgps), such as LAMP1 (intermediate SCV; [@cdg517c11]; [@cdg517c30]; [@cdg517c24]; [@cdg517c32]). The late SCV represents the third stage of maturation which begins 3--4 h after invasion. It requires the intracellular synthesis of bacterial proteins and is characterized by the further recruitment of lgps and the initiation of Sif formation. Sifs are tubular structures enriched in lgps and which appear to be contiguous with the SCV ([@cdg517c12]). However, the SCV does not accumulate significant amounts of the lysosomal enzymes that are normally delivered to a maturing phagolysosome by the cation-independent mannose-6-phosphate receptor ([@cdg517c11]; [@cdg517c30]). Interactions between the SCV and the endocytic pathway are therefore selective, and this unique trafficking pathway creates an environment permissive for bacterial cell division, which begins after a lag period of 3--4 h after invasion ([@cdg517c12]).

Intracellular replication of *S.typhimurium* involves a large number of virulence proteins, including the type III secretion system (TTSS), encoded by the SPI-2 pathogenicity island ([@cdg517c25]; [@cdg517c7]; [@cdg517c17]). This TTSS translocates effector proteins into the vacuolar membrane and cytosol of the host cell. Several effectors have been identified in recent years, encoded both within and outside the pathogenicity island. SpiC is a SPI-2-encoded protein that prevents interactions between SCVs and endocytic compartments in macrophages ([@cdg517c35]). SifA is encoded outside SPI-2, and is required for maintenance of the vacuolar membrane, most likely by facilitating the recruitment and fusion of vesicles with the SCV ([@cdg517c2]). SifA is also required for the formation of Sifs ([@cdg517c33]). SCV membrane dynamics are also influenced by the action of another effector, the predicted acyl transferase SseJ ([@cdg517c31]). Several other effectors have been described, but the functions of most of them are not understood ([@cdg517c38]).

While interactions between the SCV and markers of the endocytic pathway have been studied in depth, little is known about the spatial distribution of SCVs within infected cells and the potential relevance of this to bacterial multiplication. We show here that the majority of SCVs become surrounded by Golgi membranes 4 h after invasion of epithelial cells, a process that is dependent on the SPI-2 TTSS effector SseG. Mutational analysis of this protein identified a Golgi-targeting domain and defined further regions that are required for recruitment of SCVs to the Golgi network. The physiological relevance of Golgi targeting by *Salmonella* is demonstrated by the requirement of both SseG and an intact Golgi network for *Salmonella* replication. Therefore, SCV--Golgi interactions represent a crucial stage in the intracellular life cycle of *Salmonella*.

Results
=======

Salmonella localizes to the Golgi network in epithelial cells
-------------------------------------------------------------

To investigate the intracellular localization of *Salmonella*, HeLa epithelial cells were infected with GFP-expressing *S.typhimurium* and analysed by confocal immunofluorescence microscopy. Developing microcolonies usually comprised tight clusters of bacteria, positioned close to the nucleus (Figures [1](#cdg517f1){ref-type="fig"}A and [2](#cdg517f2){ref-type="fig"}A) and were often found closely associated with the Golgi network. Confocal X/Z reconstructions revealed that these microcolonies were partially or completely enveloped by Golgi membranes (Figure [1](#cdg517f1){ref-type="fig"}A; Supplementary figure S1 available at *The EMBO Journal* Online). This phenomenon was observed using antibodies against a variety of Golgi proteins, including giantin and Golgi matrix protein 130 (GM130) (Figure [1](#cdg517f1){ref-type="fig"}A and data not shown). Similar results were obtained using an antibody against TGN46, a glycoprotein localized primarily in the *trans*-Golgi network (TGN) (Figure [1](#cdg517f1){ref-type="fig"}B). In contrast, calreticulin, an endoplasmic reticulum (ER) luminal protein, was not associated with microcolonies. As expected ([@cdg517c32]), there was no association between bacteria and early or recycling endosomal markers, including EEA1 and the transferrin receptor (data not shown). At 8 h after invasion, 84 ± 6% of microcolonies of GFP-expressing wild-type bacteria were associated with Golgi membranes. The labelled Golgi proteins were concentrated in the area around the developing microcolony, rarely between individual SCVs.

To determine if Golgi proteins co-localized with LAMP1, a marker of the SCV membrane ([@cdg517c24]; [@cdg517c3]), infected cells were labelled with antibodies against LAMP1 and either giantin or TGN46. Neither Golgi protein was found to co-localize extensively with LAMP1 present on the vacuolar membrane, but frequent discrete points of co-localization were observed with both markers (arrowheads, Figure [1](#cdg517f1){ref-type="fig"}B). Neither COPI nor COPII coat proteins, which mediate vesicle formation within the secretory pathway, were recruited to the SCV membrane (data not shown). To determine whether SCV membranes were fused with Golgi membranes, infected HeLa cells were examined by transmission electron microscopy. SCVs were frequently found within 50--100 nm of Golgi cisternae (Figure [1](#cdg517f1){ref-type="fig"}C), and in some cases less than 50 nm. However, there was no evidence of fusion between SCV and Golgi membranes in over 50 infected cells analysed.

In uninfected HeLa cells, the Golgi network has a relatively compact appearance (asterisk, Figure [2](#cdg517f2){ref-type="fig"}A). In contrast, by 8 h after infection, the morphology of the network was frequently distorted, with the bacterial microcolony in the centre, suggesting that Golgi membranes are displaced by the presence of the growing microcolony (Figure [1](#cdg517f1){ref-type="fig"}A and arrowhead, Figure [2](#cdg517f2){ref-type="fig"}A). Association of *S.typhimurium* with the Golgi network was also observed in the human small intestinal epithelial cell line INT 407, but not in RAW 264.7 or elicited peritoneal murine macrophages, where replicating bacteria were frequently perinuclear, but neither associated in tight clusters nor surrounded by Golgi membranes (data not shown).

Association with the Golgi requires the SPI-2 TTSS effector SseG
----------------------------------------------------------------

We next investigated whether bacterial virulence proteins that are released intracellularly are involved in *Salmonella*--Golgi interactions. HeLa cells were infected with different mutant strains, then fixed and analysed by confocal microscopy for bacterial association with the Golgi network. SCVs were considered Golgi-associated if they were at least partially surrounded by Golgi membranes. The percentage of wild-type bacteria associated with the Golgi steadily increased to ∼80% over a 10 h period. However, a strain carrying a mutation in *ssaV*, which is defective for secretion of all SPI-2 TTSS effector proteins, had a significantly reduced level of association with the Golgi network; \<20% of bacteria were associated with the Golgi at any time during the experiment (Figure [2](#cdg517f2){ref-type="fig"}A and B). Although *ssaV* mutant bacteria remained predominantly perinuclear, in contrast to the wild-type strain they displayed a scattered distribution (Figure [2](#cdg517f2){ref-type="fig"}A). No differences were observed between the wild-type and strains carrying mutations in *phoP* or *spvB* (data not shown), two virulence loci that are involved in growth of *Salmonella* in macrophages ([@cdg517c18]). To identify the SPI-2 effector responsible for this phenotype, strains carrying mutations in genes encoding different SPI-2-translocated proteins were examined. Whereas *sseJ* and *sseI* mutant strains were indistinguishable from the wild-type, an *sseG* mutant strain had a phenotype similar to that of the *ssaV* mutant (Figure [2](#cdg517f2){ref-type="fig"}A and C). The Golgi-targeting defect of the *sseG* mutant could be attributed to a lack of SseG because a plasmid containing the wild-type *sseG* allele restored association with the Golgi to the level of the wild-type strain (Figure [2](#cdg517f2){ref-type="fig"}C). Inactivation of SseG leads to a replication defect in macrophages and moderate virulence attenuation in the mouse model of systemic salmonellosis ([@cdg517c17]). SseG is predicted to have at least two transmembrane domains; its primary amino acid sequence displays no significant similarities to protein database entries, apart from a 31% similarity to SseF, which is encoded immediately downstream of *sseG* ([@cdg517c17]).

An antibody against a C-terminal peptide of SseG was used to examine the intracellular distribution of the protein. Intense labelling was typically observed outlining part of the bacterial microcolony, and also in peripheral punctate structures (Figure [3](#cdg517f3){ref-type="fig"}A and B). SseG co-localized with LAMP1 in the SCV membrane and on Sifs (Figure [3](#cdg517f3){ref-type="fig"}B). This observation is consistent with the localization of an M45 peptide-tagged version of SseG ([@cdg517c20]). However, the peripheral SseG-positive, punctate structures did not co-localize with LAMP1. They were found mostly within the immediate vicinity of the Golgi network and occasionally co-localized with both *cis*-Golgi and TGN markers (arrowheads, Figure [3](#cdg517f3){ref-type="fig"}C).

SseG and an intact Golgi network are required for replication of Salmonella in epithelial cells
-----------------------------------------------------------------------------------------------

To establish if SseG contributes to growth of *S.typhimurium* in epithelial cells, intracellular replication assays were carried out. The numbers of wild-type and complemented *sseG* mutant strains underwent an ∼50-fold increase over a 14 h period. In contrast, the *sseG* mutant numbers increased by \<10-fold over the same time period, a replication defect similar to that of the *ssaV* mutant (Figure [4](#cdg517f4){ref-type="fig"}A). Since SseG is required for both Golgi localization of bacteria and intracellular replication, we hypothesized that the Golgi network might be exploited by *Salmonella* for its replication. Therefore, the number of wild-type bacteria in Golgi-associated microcolonies was compared over time with those located elsewhere in the cell by microscopic examination. There was no significant increase in numbers of bacteria not associated with the Golgi network, whereas the numbers of Golgi-associated bacteria underwent a significant increase over a 9 h period (Figure [4](#cdg517f4){ref-type="fig"}B). This result suggests that bacterial replication is restricted to those associated with the Golgi.

To test the requirement for an intact Golgi network in intracellular growth of *Salmonella*, cells were treated 15 min after bacterial invasion with Brefeldin A (BFA). BFA inhibits nucleotide exchange on the small GTPase ADP-ribosylating factor (Arf1), which is required for formation of COPI coated vesicles ([@cdg517c6]). As a result, the Golgi network rapidly redistributes into the ER ([@cdg517c21]). BFA strongly inhibited intracellular growth of wild-type *S.typhimurium*, but had little effect on numbers of *ssaV* mutant bacteria (Figure [4](#cdg517f4){ref-type="fig"}C). However, BFA had no noticeable effect on markers of the maturation and trafficking of the SCV, such as LAMP1 recruitment and cathepsin D exclusion (data not shown). Therefore, the effects of BFA appear to be independent of the selective interactions between SCVs and the late endocytic pathway. As a further test for the requirement of a functional Golgi network in *S.typhimurium* replication, bacteria were examined in HeLa cells expressing Arf1T31N-GFP, a dominant interfering variant of Arf1 ([@cdg517c9]). A significant reduction in intracellular bacterial numbers was observed at 12 h after invasion, compared with bacterial replication in cells expressing GFP alone (Figure [4](#cdg517f4){ref-type="fig"}D). Sar1 is another small GTPase, involved in COPII-mediated vesicle formation, and its inhibition by constitutively inactive Sar1T39N prevents the formation of early secretory vesicles at ER exit sites ([@cdg517c37]). Bacterial replication was also severely inhibited in cells expressing this mutant protein (Figure [4](#cdg517f4){ref-type="fig"}D). Expression of Arf1T31N-GFP or Sar1T39N had no effect on bacterial internalization (Supplementary table S1). Together, these experiments establish that an intact and functional Golgi network is required for intracellular replication of *S.typhimurium*.

SseG is a Golgi-targeting protein
---------------------------------

To gain further insight into the function of SseG, an epitope-tagged version of the protein (myc::SseG) was expressed in HeLa cells. The protein was concentrated in a perinuclear region, where it co-localized extensively with Golgi markers including giantin (data not shown) and TGN46 (Figure [5](#cdg517f5){ref-type="fig"}A). To verify that myc::SseG was localized to the Golgi network, transfected cells were incubated with BFA for 1 h, and either fixed immediately or washed in medium lacking BFA, and incubated for a further 1 h. In all transfected cells, BFA caused extensive redistribution of myc::SseG throughout the cell, where most of it co-localized with dispersed TGN46 (Figure [5](#cdg517f5){ref-type="fig"}A). Following BFA wash-out, TGN46 moved back to its original perinuclear position and was accompanied by myc::SseG (Figure [5](#cdg517f5){ref-type="fig"}A). Subcellular fractionation of transfected cells and immunoblotting showed that SseG localized to the membrane fraction, as expected for a predicted integral membrane protein (data not shown). In transfected cells that strongly overexpressed myc::SseG, the Golgi network was disrupted. However, expression of other *Salmonella* SPI-2 secreted proteins, including two with predicted membrane-spanning domains (myc::SseC and myc::SseD), did not result in localization to the Golgi or perturbation of its structure (data not shown).

The distribution of myc::SseG within the Golgi network was further analysed by confocal microscopy using Golgi markers. Cells expressing myc::SseG also showed some co-localization with the *cis*-Golgi protein giantin. However, triple labelling with both *cis*-Golgi and TGN markers showed that there was a greater degree of co-localization between myc::SseG and TGN46 than with giantin (Figure [5](#cdg517f5){ref-type="fig"}B). Expression of myc::SseG and p58-GFP, a protein of the ER-Golgi intermediate compartment, did not result in their co-localization (data not shown).

Golgi membrane tubulation induced by BFA results in rapid redistribution of the *cis*-Golgi network into the ER ([@cdg517c22]). Although the TGN also undergoes tubulation, these tubules do not interact with the ER but instead fuse with compartments of the early endosomal network ([@cdg517c23]; [@cdg517c39]). To confirm that myc::SseG localizes preferentially to the TGN, the kinetics of redistribution of myc::SseG were analysed after treatment with BFA. HeLa cells expressing myc::SseG were incubated with BFA and fixed for immunofluorescence microscopy at short time intervals thereafter. At 2 and 4 min after BFA treatment no significant tubulation of the *cis*-Golgi was observed. However, at the same time points, myc::SseG was found on tubulating membranes that also contained TGN46 (data not shown). From 6 to 10 min after BFA treatment, myc::SseG was still detected in tubular structures containing TGN46 but did not co-localize significantly with giantin-containing tubules (Figure [5](#cdg517f5){ref-type="fig"}C). As expected, a significant proportion of SseG also co-localized with the early endosomal marker EEA1 (Supplementary figure S2). By 14 min, the majority of giantin was redistributed in the ER whereas myc::SseG remained on TGN46-containing tubules (data not shown). Although the two proteins did not co-localize completely on tubules (arrowheads, Figure [5](#cdg517f5){ref-type="fig"}C), the kinetics of tubulation of compartments containing myc::SseG and TGN46 were indistinguishable.

Depolymerization of microtubules with nocodazole causes slow dispersal of the Golgi complex ([@cdg517c8]). Short stacked cisternae assemble slowly at peripheral sites to form small structures that closely resemble intact Golgi stacks ([@cdg517c34]). Cells expressing myc::SseG were treated with nocodazole for 5 h and then analysed by labelling myc::SseG with either giantin or TGN46. There was little co-localization between myc::SseG and giantin, but a significant degree of co-localization of myc::SseG and TGN46 was observed in many of the scattered Golgi structures (Figure [5](#cdg517f5){ref-type="fig"}D). Triple labelling with anti-myc, anti-giantin and anti-TGN46 antibodies revealed that some of the peripheral structures containing myc::SseG were negative for both the *cis*-Golgi and TGN markers (data not shown). Collectively, these experiments show that a significant proportion of SseG localizes specifically to the TGN when expressed ectopically in HeLa cells.

The Golgi-targeting domain of SseG
----------------------------------

SseG has two strongly predicted transmembrane domains (TMDs), designated HR1 and HR2, and a third hydrophobic region (HR3) that could also constitute a TMD (Figure [6](#cdg517f6){ref-type="fig"}A). In addition, the N-terminal region is unusual in that 9 of the first 31 amino acids are prolines. To identify the region(s) of SseG that confer its localization to the Golgi, a series of myc-tagged truncated versions was constructed and expressed in HeLa cells after transfection. Progressive deletions from the N- and C-termini (Δ1, Δ2, Δ3, Δ4, Δ5, Δ6, Δ7) identified a 55 amino acid region including HR2 that is necessary and sufficient for Golgi targeting of SseG (Figure [6](#cdg517f6){ref-type="fig"}B). Removal of either HR2 (Δ9, Δ10, Δ11) or the region between HR2 and HR3 (Δ8) resulted in a complete loss of Golgi targeting and the mutant proteins were instead redistributed in a punctate manner throughout the cell (Figure [6](#cdg517f6){ref-type="fig"}B and C). Therefore, information in the second TMD and its carboxy-flanking region are required for Golgi targeting. Sequence comparisons between this domain and known eukaryotic and viral Golgi-targeting sequences have failed to reveal any significant similarities.

Topology of SseG and regions required for bacterial association with the Golgi
------------------------------------------------------------------------------

The results described above show that SseG is required for the association between SCVs and the Golgi network, and that this protein has a novel Golgi-targeting signal. Therefore, one can predict that additional information must be present within SseG that localizes SCVs to the Golgi network.

To identify regions of SseG that are exposed on the cytoplasmic face of Golgi membranes, we determined the membrane topology of SseG. HeLa cells expressing myc-tagged SseG were first incubated with digitonin (which renders the plasma membrane permeable to large molecules but which does not alter the integrity of secretory pathway compartments; [@cdg517c28]), then labelled with anti-myc or anti-SseG antibodies in the absence of detergent. The myc epitope serves as a marker for the N-terminus of SseG and the anti-SseG antibody recognizes the C-terminus of the protein. An antibody against a luminal epitope of galactosyltransferase (GalT) was used as a control for the integrity of Golgi membranes. Following exposure of cells to digitonin, Golgi-associated SseG was readily detected by the anti-myc and anti-SseG antibodies. However, there was no labelling of GalT unless the cells were exposed to Triton X-100, which is a non-specific membrane permeabilizing detergent. Co-labelling of GalT and SseG revealed extensive co-localization of the two proteins (Figure [7](#cdg517f7){ref-type="fig"}A).

From this experiment we conclude that both N- and C-terminal domains of Golgi-associated SseG are exposed on the cytoplasmic face of the membrane. It follows that SseG contains only two TMDs, which are most likely HR1 and HR2. Therefore, either or both N- and C-terminal regions of the protein might be involved in localizing SCVs to the Golgi network. To test this, variants of SseG were expressed in HeLa cells and assayed for their ability to restore association of the *sseG* mutant strain with the Golgi network. First, cells were transfected with a construct expressing full-length myc::SseG, then infected with GFP-expressing wild-type or *sseG* mutant bacteria for 10 h, and examined for bacterial localization. Expression of myc::SseG or mutant versions did not affect the ability of wild-type bacteria to localize efficiently to the Golgi network (Figure [7](#cdg517f7){ref-type="fig"}B), indicating that these proteins did not exert a dominant-negative effect on Golgi targeting by wild-type bacteria. Ectopically expressed myc::SseG restored Golgi localization of the *sseG* mutant strain to the level seen with the wild-type strain (Figure [7](#cdg517f7){ref-type="fig"}B). Expression of mutants Δ8 and Δ10, which were not Golgi associated, did not rescue Golgi localization to the *sseG* mutant. However, mutants Δ1, Δ4 and Δ6, which were efficiently Golgi-localized (Figure [6](#cdg517f6){ref-type="fig"}B), also failed to rescue the *sseG* mutant phenotype (Figure [7](#cdg517f7){ref-type="fig"}B). These results demonstrate that in addition to a requirement for the Golgi-targeting region of SseG, information in both the C- and N-terminal regions of the protein is required for the interaction between SCVs and the Golgi network. To determine if other SPI-2 effectors might be involved in Golgi-targeting, myc::SseG was tested for its ability to restore Golgi localization of *ssaV* (SPI-2 null mutant) bacteria. In contrast to the *sseG* mutant, Golgi localization of the *ssaV* mutant could not be rescued by ectopic expression of SseG (Figure [7](#cdg517f7){ref-type="fig"}B). This result suggests that other SPI-2 translocated effectors contribute to the process of *Salmonella* localization to the Golgi network.

Discussion
==========

SCV maturation and association with the Golgi
---------------------------------------------

After invasion of epithelial cells by *Salmonella*, the SCV begins to migrate to the perinuclear region, and undergoes three stages of maturation, which reflect selective interactions with the endocytic pathway of the host cell ([@cdg517c32]). In this work we have shown that these events are followed by a further, crucial phase of development, in which SCVs interact with the Golgi network through the action of SseG. Since this stage involves bacterial replication, we refer to it as the replicative SCV. Therefore, maturation of the SCV proceeds not only by progressive and selective interactions with the endocytic pathway but also in terms of the spatial distribution of SCVs in the host cell, and their interaction with the secretory pathway. A model of SCV trafficking in relation to its intracellular localization is shown in Figure [7](#cdg517f7){ref-type="fig"}C.

Physical continuities between SCV and Golgi membranes were not observed at the ultrastructural level, but it seems likely that transient interactions must occur, since intracellular bacterial replication can be inhibited either by perturbation of Golgi function, or by mutation of *sseG*, which prevents SCVs from localizing to the Golgi network. The close apposition of SCVs and Golgi membranes, and an associated membrane fusion machinery, could enable transient fusion events between Golgi-derived vesicles and SCVs, resulting in the acquisition of molecules required for *Salmonella* replication. Since expression of SseG in HeLa cells led to its concentration in the TGN, it seems likely that these vesicles are derived from late Golgi compartments.

In HeLa cells, vacuoles containing *Chlamydia* spp. (inclusion bodies) become fusogenic with sphingomyelin-containing exocytic vesicles that traffic between the TGN and the plasma membrane. Incorporation of Golgi-derived lipids is thought to provide a mechanism for growth and maintenance of the *Chlamydia* inclusion membrane ([@cdg517c16]). Therefore it is possible that SseG could mediate a similar function in acquiring lipids for the SCV membrane. BFA treatment of *Chlamydia*-infected cells leads to smaller, morphologically abnormal inclusions, but does not affect bacterial multiplication ([@cdg517c15]). In contrast, BFA had no effect on the integrity or morphology of the SCV membrane, as judged by LAMP1 labelling (data not shown), but strongly inhibited *Salmonella* replication. Furthermore, *Chlamydia* inclusions do not interact with endocytic organelles ([@cdg517c40]), whereas the SPI-2 effector SifA has a major role in the recruitment and probably fusion of lgp-containing vesicles to the SCV membrane ([@cdg517c31]). Indeed, mutation of *sifA* results in a strain that cannot maintain the physical integrity of its vacuolar membrane ([@cdg517c2]). Therefore *Salmonella* appears to exploit late endocytic organelles as a source of membrane that is required to enclose replicating bacteria, and it seems more likely that interactions between SCVs and the Golgi satisfy a nutritional requirement, for example by providing carbon and/or nitrogen sources which are necessary for bacterial replication.

Role of SseG in bacterial association with the Golgi
----------------------------------------------------

Two lines of evidence show that the SPI-2 TTSS effector protein SseG and its Golgi-targeting region are necessary for *S.typhimurium* association with the Golgi network. First, *sseG* mutant bacteria fail to localize to the Golgi network of infected cells. Second, this defect can be rescued efficiently by ectopic expression of full-length SseG in infected cells, but not by a version lacking the Golgi-targeting domain. In infected cells, SseG was found associated with SCVs and in peripheral punctate structures, which occasionally co-localized with Golgi markers. How then does translocated SseG account for bacterial association with the Golgi? Apart from its Golgi-targeting region, both the proline-rich N-terminal domain and information in the C-terminal 51 amino acids contribute to the localization of SCVs to the Golgi network. Furthermore, localization of *sseG* mutant but not SPI-2 null mutant bacteria to the Golgi can be rescued by the ectopic expression of SseG in HeLa cells. These results suggest the existence of another SPI-2 effector that functions together with SseG to mediate Golgi localization of SCVs. Alternatively the null mutant may be defective in earlier unrelated processes of vacuole maturation, on which SseG function is dependent. Translocated SseG might interact with its target membrane via the Golgi-targeting domain, and to another effector through its N- or C-terminal regions. It is possible that SseG is a component of a multiprotein complex that mediates interactions between SCVs and Golgi membranes.

A variety of proteins are targeted to Golgi membranes by their TMDs. These include integral membrane glycosyltransferases and several viral proteins. For example, the M protein of the coronavirus mouse hepatitis virus, which targets the TGN, has one signal in its TMD and a second signal in the cytoplasmic tail ([@cdg517c13]). In the M protein of the avian coronavirus infectious bronchitis virus, the first of three TMDs contains the signal that targets the protein to the Golgi network ([@cdg517c13]). However, no similarity between SseG and either eukaryotic or prokaryotic Golgi targeting sequences has been found. Therefore the Golgi-targeting signal present within amino acids 88 and 142 of SseG appears to be novel.

Interestingly, SseG has also been reported to be present on, and required for the formation of, Sifs ([@cdg517c14]; [@cdg517c20]). However, this process is likely to be independent of its interactions with the Golgi network, as BFA treatment does not prevent Sif formation ([@cdg517c5]; data not shown). Therefore, SseG might perform more than one function in the maturation of SCVs.

Role of SseG in Salmonella virulence
------------------------------------

Although it is clear that the *Salmonella* SPI-2 TTSS plays an important role in intracellular replication of bacteria in epithelial cells ([@cdg517c7]; [@cdg517c4]; [@cdg517c3]; [@cdg517c26]; this study) the functions of SPI-2 have been mainly studied in macrophages, which are colonized during the systemic phase of the disease in mice ([@cdg517c18]). Microscopic examination of *S.typhimurium* in primary and RAW 264.7 macrophages failed to reveal significant association of SCVs with the Golgi network. However, other evidence indicates that *S.typhimurium*--Golgi interactions might be relevant in macrophages. First, the virulence of the *sseG* mutant strain is attenuated in the murine model of infection ([@cdg517c17]). Second, the *sseG* mutant strain has a replication defect in RAW 264.7 macrophages ([@cdg517c17]), and in primary peritoneal macrophages (data not shown). Third, treatment of infected macrophages with BFA significantly inhibited *S.typhimurium* replication (Supplementary figure S3). Therefore, it seems probable that *S.typhimurium* does interact with the Golgi network in macrophages, but in a way that does not involve clustering of bacterial microcolonies within Golgi membranes.

It is well established that in epithelial cells, maturation of the SCV is dependent on a series of selective interactions with the endocytic pathway. The major conclusion to emerge from the work described here is that while these interactions are necessary for bacterial survival, they are not sufficient for intracellular replication: this requires SCV interactions with the secretory pathway. The identification of SseG as a Golgi-targeting virulence protein provides the basis for further investigation into the mechanisms by which this pathogen replicates in host cells, could provide insights into the normal functioning of the Golgi network and might ultimately offer novel approaches to inhibit bacterial growth in host cells.

Materials and methods
=====================

Bacterial strains, plasmids and growth conditions
-------------------------------------------------

The *S.typhimurium* strains used in this study were the wild-type 12023s, and its isogenic mutant derivatives: *ssaV*::aphT ([@cdg517c10]), *sseG*::aphT ([@cdg517c17]) *sseI*::pGP704 ([@cdg517c31]) and Δ*sseJ* ([@cdg517c31]). Bacteria were grown in Luria Bertani (LB) medium supplemented with ampicillin (50 µg/ml), kanamycin (50 µg/ml) or chloramphenicol (35 µg/ml) for plasmid-containing strains, as appropriate.

Plasmid pFVP25.1, carrying *gfpmut3A* under the control of the *rpsM* constitutive promoter ([@cdg517c36]), was introduced into bacterial strains for fluorescence visualization where indicated. The plasmids pCLXSN-GFP and pCLXSN-Arf1T39N-GFP ([@cdg517c19]) were provided by Dr C. Roy. The Sar1T39N plasmid ([@cdg517c37]) was obtained from Dr J. Lippincott-Schwartz. Construction of the complementing plasmid p*sseG* and the expression plasmid p*myc::sseG* are described in the Supplementary data. The computer program TMpred was used to identify membrane-spanning domains within SseG ([@cdg517c27]). Construction of plasmids used for expression of truncated versions of SseG are described in the Supplementary data.

Antibodies and reagents
-----------------------

The mouse anti-LAMP1 antibody H4A3 was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD, maintained by the University of Iowa and was used at a dilution of 1:1000. Anti-*Salmonella* goat antibody CSA-1 (Kirkegaard and Perry Laboratories) was used at a dilution of 1:400. The rabbit antibodies anti-GM130 and anti-giantin were obtained from Dr A.De Matteis and used at a dilution of 1:1000 and 1:2000, respectively. The mouse anti-GM130 antibody (Transduction Laboratories) was used at a dilution of 1:1000. The sheep anti-human TGN46 antibody (Serotec) was used at a dilution of 1:100. A rabbit antibody against human TGN46 ([@cdg517c29]) was obtained from Dr G.Banting and was used at the dilution of 1:500. The mouse anti-c-myc antibody 9E10 (Santa Cruz Biotechnology) was used at a dilution of 1:100. An antibody to galactosyltransferase was obtained from Dr E.Berger and was used at a dilution of 1:4 ([@cdg517c1]). Rhodamine Red X (RRX)-, Cyanine 2-, Cyanine 5 (Cy5)- and aminomethylcoumarin acetate-conjugated donkey anti-mouse, anti-rabbit and anti-goat antibodies (Jackson Immunoresearch Laboratories) were used at a dilution of 1:400. RRX- and Cy5-conjugated donkey anti-sheep antibodies (Jackson Immunoresearch Laboratories) were used at dilutions of 1:100 and 1:600, respectively. BFA (Sigma) was used at 5 µg/ml. At this concentration BFA was not cytotoxic to HeLa cells and did not affect *S.typhimurium* growth in LB medium over 16 h. Nocodazole (Calbiochem) was used at a final concentration of 10 µg/ml.

Affinity purification of the anti-SseG antibody
-----------------------------------------------

A peptide with the sequence SSPLYRLLAQVTPEQRAPE corresponding to the last 19 amino acids of SseG was conjugated to keyhole limpet haemocyanin and this was used to immunize rabbits. Polyclonal rabbit serum was affinity purified using Affi-Gel 15 (BioRad), to which the peptide had been coupled, following the manufacturer's procedure.

Cell culture
------------

HeLa (clone HtTA1) cells were kindly provided by Dr S.Méresse. The INT 407 cell line U510 was a gift from Dr A.L.Servin. Cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and 2 mM glutamine at 37°C in 5% CO~2~.

Bacterial infection of cultured cells and replication assays
------------------------------------------------------------

HeLa cells were infected with equivalent numbers of exponential phase *S.typhimurium* strains, as described previously ([@cdg517c2]). In order to follow a synchronized population of bacteria, HeLa cells were washed after 15 min of exposure to *S.typhimurium* and subsequently incubated in medium containing gentamicin to kill extracellular bacteria. For enumeration of intracellular bacteria, HeLa cells were washed three times with phosphate-buffered saline, lysed with 0.1% Triton X-100 for 10 min and a dilution series was plated onto LB agar.

Microscopy
----------

For electron microscopy, samples were prepared as described previously for HeLa cells ([@cdg517c3]). For immunofluorescence, cell monolayers were fixed and labelled as described previously ([@cdg517c3]). For the affinity purified anti-SseG antibody, coverslips were permeabilized for 10 min with 0.1% Triton X-100 and then labelled as described above, in the absence of saponin. Samples were analysed using a confocal laser scanning microscope (LSM510; Zeiss).

Transfection of HeLa cells
--------------------------

HeLa cells were transiently transfected by the calcium phosphate DNA precipitation method as described previously ([@cdg517c31]). Bacterial infection of transfected HeLa cells was performed as described above, 14 h after DNA addition, and cells were fixed 24 h after DNA addition (10 h after infection). To determine the topology of myc::SseG, HeLa cells were transfected for 24 h with 2 µg of DNA using Polyfect (Quiagen) and then permeabilized with 25 µg/ml digitonin (Calbiochem) for 5 min on ice ([@cdg517c28]). Cells were then fixed with PFA and labelled with antibodies in the absence of detergent.

Quantification of Salmonella association with the Golgi network
---------------------------------------------------------------

Quantification of the number of bacteria associated with the Golgi network was performed by confocal microscopy. Only bacteria that were either completely or at least 50% surrounded by the labelled Golgi marker were counted as being Golgi associated. Bacterial clusters that were found adjacent to the Golgi but did not fulfil the above criteria were counted as non-associated. At least 50 host cells, corresponding to more than 100 bacteria, were scored blind in each experiment and all experiments were repeated three times.

Supplementary data
------------------

Supplementary data are available at *The EMBO Journal* Online.
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![**Fig. 1.** *Salmonella* associates with the Golgi network in HeLa cells. (**A**) Upper panel, confocal immunofluorescence micrograph showing the subcellular localization of GFP-expressing wild-type *S.typhimurium* (wt-GFP, green) in relation to the *cis*-Golgi protein giantin (red), and the host cell (DIC in merged image), 8 h after invasion. Scale bar corresponds to 5 µm. Lower panel shows a 360° rotation on the *y*-axis of a 3D reconstruction obtained from a z-stack of the cell shown in the upper panel. Scale bar corresponds to 2 µm. (**B**) Infected cells were labelled for TGN46 (red), *Salmonella* (blue) and LAMP1, a marker of the SCV membrane (green). Points of co-localization between LAMP1 and TGN46 are indicated by arrowheads. Scale bar corresponds to 5 µm. (**C**) Transmission electron micrographs of representative HeLa cells showing wild-type *Salmonella* (B) in close proximity to Golgi cisternae (G). The nucleus is marked as (N). Scale bars correspond to 500 nm.](cdg517f1){#cdg517f1}

![**Fig. 2.** *Salmonella*--Golgi association requires the SPI-2 TTSS effector protein SseG. (**A**) Intracellular distribution of GFP-expressing wild-type (wt), *ssaV* or *sseG* mutant strains in relation to giantin, 8 h after invasion of HeLa cells. Arrowhead indicates a distorted Golgi structure associated with a bacterial microcolony. Asterisk indicates compact Golgi network in an uninfected cell. Scale bars correspond to 10 µm. (**B**) Time course showing the increased association of wild-type *S.typhimurium* with the Golgi network (revealed by giantin labelling) in contrast to the *ssaV* mutant strain. Standard deviations from the mean are shown; results correspond to three independent experiments. (**C**) Association of SPI-2 effector mutant strains with the Golgi, 8 h after invasion of HeLa cells. Standard deviations from the mean are shown; results correspond to three independent experiments.](cdg517f2){#cdg517f2}

![**Fig. 3.** Intracellular distribution of SseG in HeLa cells. (**A**) Confocal immunofluorescence microscopy of HeLa cells infected for 10 h by GFP-expressing wild-type strain or the *sseG* mutant as a control. Cells were labelled with the anti-SseG antibody (red). Scale bars correspond to 5 µm. (**B**) Confocal immunofluorescence microscopy of HeLa cells infected for 10 h by wild-type *S.typhimurium*. Boxed areas shown in higher magnification below show co-localization between SseG (green) and LAMP1 (red) on a Sif and SCV membrane. *Salmonella typhimurium* was labelled with an anti-*Salmonella* antibody (blue). Punctate labelling of SseG can also be seen in the vicinity of the microcolony. Scale bar corresponds to 5 µm. (**C**) Distribution of SseG in relation to the Golgi network in HeLa cells infected for 10 h with wild-type bacteria (blue in merged image). Arrowheads indicate points of co-localization between SseG (red) and either GM130 (green, upper panel) or TGN46 (green, lower panel). Scale bars correspond to 5 µm.](cdg517f3){#cdg517f3}

![**Fig. 4.** Interaction of *Salmonella* with the Golgi network is required for intracellular replication in HeLa cells. (**A**) Intracellular replication of *S.typhimurium* strains in HeLa cells. The values shown are representative of three independent experiments and indicate the fold increase calculated as a ratio of the intracellular bacteria between 16 and 2 h after invasion. Each infection was performed in triplicate and the standard errors from the mean are shown. (**B**) Analysis of the number of bacteria per microcolony in HeLa cells during a 9 h time course. Microcolonies associated with the Golgi network are compared with those found elsewhere in the cell. Values represent the mean of three independent experiments and the standard deviations from the mean are shown. (**C**) Intracellular replication of *S.typhimurium* strains in HeLa cells treated with BFA. The assay was carried out as for (A) above, except that BFA (5 µg/ml) was added at 15 min after invasion. There was no statistical difference between the numbers of internalized bacteria in treated or untreated cells at the 2 h time point. (**D**) Effect of expression of SarT39N or ArfT31N on intracellular replication of wild-type *S.typhimurium*. HeLa cells were transfected for 14 h, then infected for a further 8--12 h. Values represent the percentage of host cells containing more than 20 bacteria at different time points after invasion. The percentage of untransfected cells with more than 20 *sseG* mutant bacteria is shown on the right. Values represent the means of three independent experiments and the standard deviations from the mean are shown.](cdg517f4){#cdg517f4}

![**Fig. 5.** Expression of myc::SseG in HeLa cells results in its localization to the Golgi network. (**A**) Cells expressing a myc-tagged version of SseG (green) were co-labelled with an antibody against TGN46 (red), and examined by confocal microscopy. The majority of myc::SseG co-localizes with TGN46 (upper panel) and its redistribution follows that of the TGN marker upon BFA treatment (middle panel). BFA washout leads to recovery of a compact Golgi structure, and the re-localization of myc::SseG (lower panel). Scale bars correspond to 5 µm. (**B**) Cells expressing myc::SseG (green) were triple labelled with anti-myc (green), anti-TGN46 (red) and anti-giantin (blue) antibodies. (**C**) Cells expressing myc::SseG (green) were treated with BFA for 10 min, fixed and labelled with either anti-giantin or anti-TGN46 antibodies. In the upper panel the arrowheads indicate tubules containing myc::SseG (green) which does not co-localize with giantin (red). Scale bar corresponds to 5 µm. In the lower panel, myc::SseG co-localizes with TGN46 in tubules. Arrowheads indicate tubulating regions shown at a higher magnification in insets. (**D**) Distribution of myc::SseG and Golgi markers after exposure of transfected cells to nocodazole. Cells were labelled with anti-myc (green) and either anti-giantin (red, upper panel) or anti-TGN46 (red, lower panel) antibodies. Scale bars correspond to 5 µm.](cdg517f5){#cdg517f5}

![**Fig. 6.** Identification of Golgi-targeting regions of SseG. (**A**) Amino acid sequence of SseG. Hydrophobic regions HR1, HR2 and HR3 are underlined in blue, red and green, respectively. The Golgi targeting region is highlighted in yellow. Prolines in the N-terminal 31 amino acids are in bold. (**B**) Schematic representation of truncated polypeptides derived from myc::SseG. The extent of each deletion is shown in parentheses to the left of each construct. The ability of each polypeptide to associate with the Golgi is indicated to the right of each construct. (**C**) Representative images of Δ6 (upper panel) showing extensive co-localization with TGN46 and Δ8 (lower panel) showing a scattered distribution, with no co-localization with the Golgi marker. Scale bars correspond to 5 µm.](cdg517f6){#cdg517f6}

![**Fig. 7.** Topology of SseG and functional activity of mutant polypeptides. (**A**) HeLa cells expressing myc::SseG were permeabilized with Triton X-100 (control) or digitonin and labelled with antibodies against myc, SseG or a luminal epitope of human galactosyltransferase (GalT). Scale bars correspond to 5 µm. (**B**) HeLa cells expressing wild-type or mutant myc::SseG polypeptides were infected for 10 h with GFP-expressing wild-type, *ssaV* or *sseG* mutant *S.typhimurium*. Cells were labelled with anti-myc and anti-giantin antibodies, and the level of bacterial association with the Golgi network was determined in both transfected and untransfected cells. Values represent means of three independent experiments and the standard deviations from the mean are shown. (**C**) Model of SCV trafficking in relation to localization within epithelial cells. Following host cell invasion, development of the early and intermediate SCV proceeds by progressive and selective interactions with compartments of the endocytic pathway (LAMP1 and cathepsin D are shown as yellow and pink symbols, respectively), as bacteria (green) migrate to a perinuclear location. This leads to the formation of the late SCV. The translocation of the SPI-2 TTSS effector SifA is required for recruitment of lgp-containing vesicles and the formation of Sifs, while SseG localizes SCVs to the Golgi network. As a consequence of this, the replicative phase of development can begin through acquisition of nutrients that enable bacterial replication, and membrane which encloses the growing population of intracellular bacteria. EE, early endosome; LE, late endosome; LYS, lysosome.](cdg517f7){#cdg517f7}
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